Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2B3-101 in Solid Tumors and Brain Metastases
NCT01386580Phase 2Completed
- Sponsor
- 2-BBB Medicines
- Start
- Jul 2011
- Primary completion
- Dec 2014
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 4
01
Overview
Phase 2, open-label trial of doxorubicin glutathione pegylated liposomal in solid tumor, brain metastases, malignant glioma and 3 more (4 arms), sponsored by 2-BBB Medicines. Primary endpoints: Safety and Tolerability of 2B3-101 at 16 months, Maximum Tolerated Dose at 16 months and 2 more. Started Jul 2011; status: completed.
02
Drugs
doxorubicin glutathione pegylated liposomal
03
Conditions
solid tumorbrain metastasesmalignant gliomabreast cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01386580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386580.